F S&P 500
5,127.00 +44.75 (+0.88%) F Dow Jones
38,368.00 +80.00 (+0.21%) F Nasdaq
17,770.00 +202.50 (+1.15%) E-mini Russell 2000 Index Futur
1,991.40 -1.80 (-0.09%) Petróleo
84.01 +0.44 (+0.53%) Oro
2,349.00 +6.50 (+0.28%)
Regeneron Pharmaceuticals, Inc. (REGN)
Fuera de horario:
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
United States
914 847 7000
https://www.regeneron.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 13,450
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Leonard S. Schleifer M.D., Ph.D. | Co-Founder, President, CEO & Co-Chairman | 7M | N/D | 1953 |
| Dr. George D. Yancopoulos M.D., Ph.D. | Co-Founder, President, Chief Scientific Officer & Co-Chairman | 6.59M | N/D | 1960 |
| Dr. Andrew J. Murphy Ph.D. | Executive Vice President of Research | 1.62M | 19.39M | 1959 |
| Mr. Daniel P. Van Plew | Executive VP and GM of Industrial Operations & Product Supply | 1.95M | 45.28M | 1973 |
| Ms. Marion E. McCourt | Executive Vice President of Commercial | 1.5M | 4.25M | 1960 |
| Mr. Christopher R. Fenimore CPA | Senior VP of Finance & CFO | N/D | N/D | 1971 |
| Ms. Patrice Gilooly | Senior Vice President of Quality Assurance & Operations | N/D | N/D | N/D |
| Mr. Bob McCowan | Senior VP of IT & Chief Information Officer | N/D | N/D | N/D |
| Mr. Ryan Crowe | Senior Vice President of Investor Relations & Strategic Analysis | N/D | N/D | N/D |
| Mr. Joseph J. LaRosa | Executive VP, General Counsel & Secretary | 1.75M | 23.23M | 1959 |
Descripción
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Gestión corporativa
La calificación ISS Governance QuickScore de Regeneron Pharmaceuticals, Inc. a partir del 1 de abril de 2024 es 10. Las puntuaciones principales son Auditoría: 9; Junta: 10; Derechos del accionista: 10; Compensación: 9.
